Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)

NCT06087276 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

1000

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Tremor

Interventions

DRUG: 60 mg ulixacaltamide
DRUG: Placebo

Sponsor

Praxis Precision Medicines